AIMS: The GISSI-HF trial showed that n-3 polyunsaturated fatty acids (PUFA), but not rosuvastatin, reduce morbidity and mortality in patients with symptomatic heart failure (HF) of any cause. The aim of this echocardiographic substudy of GISSI-HF was to investigate the effects of n-3 PUFA and of rosuvastatin on left ventricular (LV) function in such patients. METHODS AND RESULTS:Six hundred and eight chronic HF patients were randomized to n-3 PUFA (n=312) or placebo (n=296); a second randomization was performed to rosuvastatin (n=212) or placebo (n=207). Echocardiographic examinations were recorded at baseline and at 1, 2, and 3 years; offline analysis was performed by a core laboratory to ensure consistent quantitative analysis. Baseline LV ejection fraction (EF) was 30% (95%CI 29-31). Left ventricular ejection fraction increased with n-3 PUFA by 8.1% at 1 year, 11.1% at 2 years, and 11.5% at 3 years vs. 6.3% at 1 year, 8.2% at 2 years, and 9.9% at 3 years in the placebo group (P=0.0050). No other echocardiographic parameter changed significantly. Rosuvastatin effects were not statistically significant. CONCLUSION:n-3 PUFA can provide a small but statistically significant advantage in terms of LV function in patients with symptomatic HF of any aetiology, already treated with recommended therapies.
RCT Entities:
AIMS: The GISSI-HF trial showed that n-3 polyunsaturated fatty acids (PUFA), but not rosuvastatin, reduce morbidity and mortality in patients with symptomatic heart failure (HF) of any cause. The aim of this echocardiographic substudy of GISSI-HF was to investigate the effects of n-3 PUFA and of rosuvastatin on left ventricular (LV) function in such patients. METHODS AND RESULTS: Six hundred and eight chronic HF patients were randomized to n-3 PUFA (n=312) or placebo (n=296); a second randomization was performed to rosuvastatin (n=212) or placebo (n=207). Echocardiographic examinations were recorded at baseline and at 1, 2, and 3 years; offline analysis was performed by a core laboratory to ensure consistent quantitative analysis. Baseline LV ejection fraction (EF) was 30% (95%CI 29-31). Left ventricular ejection fraction increased with n-3 PUFA by 8.1% at 1 year, 11.1% at 2 years, and 11.5% at 3 years vs. 6.3% at 1 year, 8.2% at 2 years, and 9.9% at 3 years in the placebo group (P=0.0050). No other echocardiographic parameter changed significantly. Rosuvastatin effects were not statistically significant. CONCLUSION:n-3 PUFA can provide a small but statistically significant advantage in terms of LV function in patients with symptomatic HF of any aetiology, already treated with recommended therapies.
Authors: Savina Nodari; Marco Triggiani; Alessandra Manerba; Giuseppe Milesi; Livio Dei Cas Journal: Intern Emerg Med Date: 2011-10 Impact factor: 3.397
Authors: Dariush Mozaffarian; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Donna Spiegelman; Frank M Sacks; Eric B Rimm; David S Siscovick Journal: Ann Intern Med Date: 2011-08-02 Impact factor: 25.391
Authors: Erinne R Dabkowski; Kelly A O'Connell; Wenhong Xu; Rogerio F Ribeiro; Peter A Hecker; Kadambari Chandra Shekar; Caroline Daneault; Christine Des Rosiers; William C Stanley Journal: Cardiovasc Drugs Ther Date: 2013-12 Impact factor: 3.727
Authors: Wei Jiang; Harry Oken; Mona Fiuzat; Linda K Shaw; Carolyn Martsberger; Maragatha Kuchibhatla; Rima Kaddurah-Daouk; David C Steffens; Rebecca Baillie; Michael Cuffe; Ranga Krishnan; Christopher O'Connor Journal: J Cardiovasc Transl Res Date: 2011-11-01 Impact factor: 4.132
Authors: Tatiana F Galvao; Ramzi J Khairallah; Erinne R Dabkowski; Bethany H Brown; Peter A Hecker; Kelly A O'Connell; Karen M O'Shea; Hani N Sabbah; Sharad Rastogi; Caroline Daneault; Christine Des Rosiers; William C Stanley Journal: Am J Physiol Heart Circ Physiol Date: 2012-10-26 Impact factor: 4.733
Authors: Erik Øie; Rolf K Berge; Thor Ueland; Christen P Dahl; Thor Edvardsen; Jan Otto Beitnes; Pavol Bohov; Pål Aukrust; Arne Yndestad Journal: Lipids Date: 2012-12-25 Impact factor: 1.880